Oliver Tomé

988 total citations
14 papers, 128 citations indexed

About

Oliver Tomé is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Reproductive Medicine. According to data from OpenAlex, Oliver Tomé has authored 14 papers receiving a total of 128 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 4 papers in Reproductive Medicine. Recurrent topics in Oliver Tomé's work include Cancer Treatment and Pharmacology (7 papers), Advanced Breast Cancer Therapies (6 papers) and HER2/EGFR in Cancer Research (5 papers). Oliver Tomé is often cited by papers focused on Cancer Treatment and Pharmacology (7 papers), Advanced Breast Cancer Therapies (6 papers) and HER2/EGFR in Cancer Research (5 papers). Oliver Tomé collaborates with scholars based in Germany, United States and Switzerland. Oliver Tomé's co-authors include Frederik Wenz, Uta Kraus-Tiefenbacher, Anke Keller, Marc Sütterlin, Grit Welzel, Carsten Herskind, E. Blank, Martin Borggrefe, Frank Lohr and Dietmar Dinter and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Oliver Tomé

13 papers receiving 124 citations

Peers

Countries citing papers authored by Oliver Tomé

Since Specialization

Citations

This map shows the geographic impact of Oliver Tomé's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Tomé with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Tomé more than expected).

Fields of papers citing papers by Oliver Tomé

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver Tomé. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Tomé. The network helps show where Oliver Tomé may publish in the future.

Co-authorship network of co-authors of Oliver Tomé

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Tomé. A scholar is included among the top collaborators of Oliver Tomé based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Tomé. Oliver Tomé is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer – the SERAPHINA study 2025 ·Journal of Cancer Research and Clinical Oncology ·Andreas Schneeweiß, (unknown), Marc Thill, Marion van Mackelenbergh, Frederik Marmé, Hans Tesch, Tanja Fehm, Tjoung‐Won Park‐Simon, Lothar Häberle, (unknown), Oliver Tomé, (unknown), (unknown), Matthias Ruebner, Erik Belleville, D. Wallwiener, Sara Y. Brucker, Andreas D. Hartkopf	0
2	Circadian rhythm disruption by PARP inhibitors correlates with treatment toxicity in patients with ovarian cancer and is a predictor of side effects 2025 ·EBioMedicine ·Deeksha Malhan, Janina Hesse, (unknown), Karmen Stankov, (unknown), (unknown), (unknown), (unknown), Bastian Czogalla, (unknown), Martin C. Koch, (unknown), Oliver Tomé, Ralf Witteler, Mustafa Deryal, Michael Eichbaum, Jalid Sehouli, (unknown), Angela Relógio	2
3	Low probability of disease cure in advanced ovarian carcinomas before the PARP inhibitor era 2022 ·British Journal of Cancer ·Benoît You, (unknown), Michel Tod, Gabe S. Sonke, Hugo M. Horlings, Roy F.P.M. Kruitwagen, Andreas du Bois, Frédèric Selle, Timothy Perren, Jacobus Pfisterer, Florence Joly, Adrian Cook, Marie Christine Kaminsky, K. Wollschlaeger, Alain Lortholary, Oliver Tomé, Alexandra Léary, Gilles Freyer, Maaike A. van der Aa, Olivier Colomban	6
4	Bevacizumab Combined with Platinum–Taxane Chemotherapy as First-Line Treatment for Advanced Ovarian Cancer: Results of the NOGGO Non-Interventional Study (OTILIA) in 824 Patients 2021 ·Cancers ·Jalid Sehouli, Alexander Mustea, (unknown), Maren Keller, Rolf Richter, Oliver Tomé, Hannah Woopen, (unknown), Jacek Grabowski, Robert Armbrust, Pauline Wimberger	4
5	First-line bevacizumab-containing therapy for HER2-negative locally advanced/metastatic breast cancer: Real-world experience from >2000 patients treated in the multicentre AVANTI study 2021 ·The Breast ·Volkmar Müller, Markus Ruhnke, Oliver Hoffmann, Andrea Gräfe, Oliver Tomé, W. Fett, Harald-Robert Bruch, (unknown), Andreas Schneeweiß	4
6	Effect of hypertension (HTN) on progression-free survival (PFS) in patients (pts) receiving front-line bevacizumab (BEV) for primary advanced ovarian cancer (OC) in the NOGGO single-arm OTILIA study: A post hoc analysis in 808 pts. 2018 ·Journal of Clinical Oncology ·Robert Armbrust, Pauline Wimberger, Alexander Mustea, (unknown), Maren Keller, Rolf Richter, (unknown), (unknown), (unknown), Oliver Tomé, Jalid Sehouli, (unknown)	1
7	Analysis of everolimus starting dose as prognostic marker in HR+ mBC patients treated with everolimus (EVE) + exemestane (EXE): Results of the 3rd interim analysis of the non-interventional trial BRAWO. 2017 ·Journal of Clinical Oncology ·Peter A. Fasching, Eva‐Maria Grischke, Florian Schuetz, Thomas Decker, Christoph Uleer, Christoph Salat, (unknown), Marcus Schmidt, Christoph Mundhenke, Hans Tesch, Christian Jackisch, Pauline Wimberger, Bahriye Aktas, (unknown), Oliver Tomé, Wilhelm Bloch, (unknown), Thomas Fischer, Jöerg Schubert, (unknown)	3
8	A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO) 2016 ·Journal of Cancer Research and Clinical Oncology ·Jalid Sehouli, Oliver Tomé, (unknown), Oumar Camara, (unknown), (unknown), Beate Rautenberg, Radoslav Chekerov, Mustafa Zelal Muallem, Michael P. Lux, Tanja Trarbach, G. Gitsch	14
9	Abstract P5-19-12: Subgroup analysis on efficacy in the routine treatment - Results of the 2nd interim analysis of BRAWO, the non-interventional trial "Breast Cancer Treatment with Everolimus and Exemestane for HR+ Women" 2015 ·Cancer Research ·Christian Jackisch, Eva‐Maria Grischke, Andreas Schneeweiß, Thomas Decker, Christoph Uleer, Frank Förster, Oliver Tomé, Pauline Wimberger, Christian M. Kurbacher, (unknown), Nadia Harbeck, Christoph Mundhenke, Sherko Küemmel, Mathias Muth, (unknown), Wilhelm Bloch, Hans Tesch, Diana Lüftner, Florian Schütz, Peter A. Fasching	3
10	Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer 2014 ·Breast Cancer Research and Treatment ·Hans‐Joachim Lück, Kristina Lübbe, Mattea Reinisch, Nicolaì Maass, Gabriele Feisel-Schwickardi, Oliver Tomé, Wolfgang Janni, Mustafa Aydoğdu, Tanja Neunhöffer, Angelika Ober, Bahriye Aktas, Tjoung‐Won Park‐Simon, Claudia Schumacher, Heinz‐Gert Höffkes, Thomas Illmer, (unknown), Keyur Mehta, Gϋnter von Minckwitz, Valentina Nekljudova, Sibylle Loibl	19
11	A randomized phase III study to determine the efficacy of capecitabine in addition to a taxane and bevacizumab as first-line therapy in patients with metastatic breast cancer. 2013 ·Journal of Clinical Oncology ·Hans-Joachim Lueck, (unknown), Joachim Bischoff, Nicolaì Maass, (unknown), Oliver Tomé, Wolfgang Janni, Mustafa Aydoğdu, (unknown), Angelika Ober, Bahriye Aktas, Tjoung‐Won Park‐Simon, Claudia Schumacher, Heinz‐Gert Hoeffkes, Thomas Illmer, (unknown), Keyur Mehta, Valentina Nekljudova, Sibylle Loibl, Gϋnter von Minckwitz, (unknown)	4
12	Multicenter Phase II Study with Weekly Bendamustine and Paclitaxel as First- or Later-Line Therapy in Patients with Metastatic Breast Cancer: RiTa II Trial 2011 ·Breast Care ·Sibylle Loibl, Gabriele Doering, Lothar Müller, (unknown), Roberto L. Müller, Oliver Tomé, W. Wiest, (unknown), Valentina Nekljudova, Gϋnter von Minckwitz	1
13	Ist die Kardiotoxizität der Radiotherapie im Rahmen des Brusterhalts überhaupt noch relevant, und könnte sie durch Mehrfelder-IMRT gesenkt werden? 2009 ·Strahlentherapie und Onkologie ·Frank Lohr, Felix Heggemann, Theano Papavassiliu, (unknown), Oliver Tomé, Dietmar Dinter, Barbara Dobler, Uta Kraus-Tiefenbacher, Martin Borggrefe, Frederik Wenz	19
14	Early initiation of external beam radiotherapy (EBRT) may increase the risk of long-term toxicity in patients undergoing intraoperative radiotherapy (IORT) as a boost for breast cancer 2008 ·The Breast ·Frederik Wenz, Grit Welzel, Anke Keller, E. Blank, (unknown), Carsten Herskind, Oliver Tomé, Marc Sütterlin, Uta Kraus-Tiefenbacher	48

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact